Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy

被引:23
作者
Isharwal, Sumit [1 ]
Miller, Michael Craig
Epstein, Jonathan I. [1 ]
Mangold, Leslie A. [1 ]
Humphreys, Elizabeth [1 ]
Partin, Alan W. [1 ]
Veltri, Robert W. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
关键词
prostate cancer; Her-2/neu; DNA index; progression; metastasis; PCa-specific death; prognosis;
D O I
10.1002/ijc.23838
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Abnormal DNA content in tumor cells represents large scale chromosomal alterations and reflects later changes of genetic instbility. Her-2/neu oncogene is amplified in 20-30% of breast and ovarian cancer patients and is associated with poor prognosis. Therefore, we evaluated prognostic value of Her-2/neu expression and DNA content measurements in 252 clinically localized PCa patients with long-term follow-tip after radical prostatectomy for progression, metastasis and PCa-specific death. Her-2/neu expression was determined by immunohistochemistry 'v and DNA content measurements employed Feulgen-stained cancer nuclei captured using static image cytometry system. Cox proportional hazard regression and Kaplan-Meir plots were used to identify significant prognostic factors for progression, metastasis and PCa-specific death. The proportions of Her-2/neu positive and high %DNA index tumors significantly increased from nonprogressor to progressors without metastasis to progressors with metastasis (17 < 0.0001, <0.0001). Further, the proportions of Her-2/neu positive and high %DNA index, tumors significantly increased from patients who died from another cause without progression to those who (lied from another cause with progression to those (lied with PCa-specific death (p = 0.027, <0.0001). Her-2/neu expression and %DNA index were significant prognosticators for progression (P <= 0.001), metastasis (p <= 0.01) PCa-specific death (p <= 0.04) univariate analyses. Multivariately, Her-2/neu expression and %DNA index were also significant for progression (p = 0.001). metastasis (p = 0.001) and PCa-specific death (p = 0.02). When all P other clinicopathologic information is available, the increment in concordance index by addition of either Her-2/neu or DNA index was similar to 2% and of both biomarkers was similar to 3% for progression, metastasis and PCa-specific death free survival models. Therefore, patients with Her-2/neu positive and high %DNA index are at a higher risk for disease progression, metastasis and PCa-specific death. Further, Her-2/neu expression and %DNA index may be used with clinicopathologic parameters for prediction of long-term prognosis in PCa.(C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2636 / 2643
页数:8
相关论文
共 62 条
[1]   THE PROGNOSTIC VALUE OF MODAL DEOXYRIBONUCLEIC-ACID IN LOW-GRADE, LOW STAGE UNTREATED PROSTATE-CANCER [J].
ADOLFSSON, J ;
RONSTROM, L ;
HEDLUND, PO ;
LOWHAGEN, T ;
CARSTENSEN, J ;
TRIBUKAIT, B .
JOURNAL OF UROLOGY, 1990, 144 (06) :1404-1407
[2]   Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer [J].
Ahlgren, G ;
Falkmer, U ;
Gadaleanu, V ;
Abrahamsson, PA .
EUROPEAN UROLOGY, 1999, 36 (04) :314-319
[3]   DETECTION OF C-ERBB-2 RELATED PROTEIN IN SERA FROM BREAST-CANCER PATIENTS - RELATIONSHIP TO ERBB2 GENE AMPLIFICATION AND C-ERBB-2 PROTEIN OVEREXPRESSION IN TUMOR [J].
ANDERSEN, TI ;
PAUS, E ;
NESLAND, JM ;
MCKENZIE, SJ ;
BORRESEN, AL .
ACTA ONCOLOGICA, 1995, 34 (04) :499-504
[4]  
[Anonymous], J UROL
[5]  
[Anonymous], J UROL
[6]   An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level [J].
Badalament, RA ;
Miller, MC ;
Peller, PA ;
Young, DC ;
Bahn, DK ;
Kochie, P ;
ODowd, GJ ;
Veltri, RW .
JOURNAL OF UROLOGY, 1996, 156 (04) :1375-1380
[7]  
BADALAMENT RA, 1991, CANCER, V67, P3014, DOI 10.1002/1097-0142(19910615)67:12<3014::AID-CNCR2820671215>3.0.CO
[8]  
2-U
[9]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[10]  
Borre M, 1998, PROSTATE, V36, P244